Migraine management goes beyond acute symptom control and may also include preventive strategies for patients with a significant disease burden. Although triptans remain the recommended first-line treatment for acute migraine, more than 30% of patients cannot use them or do not achieve sufficient relief. Calcitonin gene-related peptide (CGRP) receptor antagonists have therefore emerged as a promising alternative treatment option.
Autoren
- Aneta Dehn
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Juvenile Idiopathic Arthritis
Early Detection and Targeted Treatment in an Interdisciplinary Setting
- Disorders of the Gut-Brain Interaction
Rome V Criteria: What Has Changed, and What Has Remained the Same?
- Tourette Syndrome
What can be done to treat this tic disorder?
- Chronic Hepatitis B: Is a Cure in Sight?
Phase III Trial of Temporary Treatment with Bepirovirsen Was Successful
- Congenital Vascular Malformations
Personalized Treatment Before a Planned Pregnancy
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Clinically Suspected Arthralgias
“Watchful waiting” or intervention?
- Tumors of the Calcaneus